Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.46 |
| ▸ | CA2 | P00918 | 5/20 | 0.46 |
| ▸ | CA4 | P22748 | 5/20 | 0.46 |
| ▸ | CA6 | P23280 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28365490 | 1.00 | CA1 (0.46) | CA1CA2CA4CA6NPC1 | |
| SCHEMBL1981599 | 1.00 | CA1 (0.46) | CA1CA2CA4CA6NPC1 | |
| SCHEMBL1188324 | 0.98 | NPC1 (0.46) | CA1CA2CA4CA6NPC1 | |
| SCHEMBL1397437 | 0.92 | NPC1 (0.45) | CA1CA2CA4CA6NPC1 | |
| SCHEMBL1278415 | 0.83 | CA1 (0.45) | CA1CA2CA4CA6NPC1 | |
| SCHEMBL14478516 | 0.83 | CA1 (0.45) | CA1CA2CA4CA6NPC1 | |
| SCHEMBL14343841 | 0.83 | CA1 (0.45) | CA1CA2CA4CA6NPC1 | |
| SCHEMBL10505153 | 0.82 | KDM4E (0.49) | CA1CA2CA4CA6NPC1 | |
| SCHEMBL3602796 | 0.82 | KDM4E (0.49) | CA1CA2CA4CA6NPC1 | |
| SCHEMBL11086697 | 0.82 | KDM4E (0.49) | CA1CA2CA4CA6NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109721-A1 | FAAH Inhibitors | IRONWOOD PHARMACEUTICALS, INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20110312945-A1 | CRTH2 MODULATORS | IRONWOOD PHARMACEUTICALS, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110312945-A1 | CRTH2 MODULATORS | IRONWOOD PHARMACEUTICALS, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110312945-A1 | CRTH2 MODULATORS | IRONWOOD PHARMACEUTICALS, INC. | 2011-12-22 | — | — | US | disclosed |
| WO-2011071996-A1 | FAAH INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-16 | — | — | WO | disclosed |
| WO-2010039982-A1 | CRTH2 MODULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010039982-A1 | CRTH2 MODULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| US-6084043-A | BRIDGED FUSED CYCLOPENTADIENE RINGS SUCH AS HEXAHYDROAZULENE WITH GIVEN SUBSTITUENTS DERIVATIVES WITH A GROUP 4B TRANSITION METAL; PRODUCES ALPHA-OLEFIN POLYMERS HAVING HIGH MELTING POINT AND HIGH MOLECULAR WEIGHT IN A HIGH YIELD | MITSUBISHI CHEMICAL CORPORATION (JP) | 2000-07-04 | — | — | US | disclosed |
| EP-0697418-B1 | Catalyst component for polymerization of alpha-olefins and process for producing alpha-olefin polymers using the same | MITSUBISHI CHEM CORP (JP) | 1998-05-06 | — | — | EP | disclosed |
| EP-0697418-A1 | Catalyst component for polymerization of alpha-olefins and process for producing alpha-olefin polymers using the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 1996-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109721-A1 | FAAH Inhibitors | FAAH, FAAH2, FAH | CA1 1176/4885CA2 2090/4885CA4 3075/4885 |
| US-20110312945-A1 | CRTH2 MODULATORS | HRH2, HRH1, NR1H2 | CA1 4306/4885CA2 2060/4885CA4 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.